Table II.
Patient characteristics and percentage of positive cells and staining intensity of BMI-1 expression.
| Proportion of stained cells, n (%) | Staining intensity, n | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Characteristics | n | 0 | 1 | 2 | 3 | 4 | 0 | 1 | 2 | 3 |
| Age | ||||||||||
| ≤60 | 21 | 1 (2.0) | 2 (18.5) | 4 (34.6) | 7 (68.2) | 7 (89.6) | 1 | 2 | 4 | 14 |
| >60 | 39 | 1 (3.6) | 3 (21.4) | 5 (40.2) | 10 (60.6) | 20 (92.5) | 1 | 4 | 11 | 23 |
| FIGO stage | ||||||||||
| I | 26 | 1 (2.8) | 5 (15.6) | 5 (32.5) | 7 (71.5) | 8 (84.2) | 1 | 8 | 10 | 7 |
| II | 20 | 1 (3.2) | 3 (16.5) | 6 (38.2) | 5 (78.6) | 5 (89.7) | 1 | 4 | 5 | 10 |
| III | 14 | 0 | 1 (19.3) | 0 | 1 (64.0) | 12 (91.4) | 0 | 0 | 6 | 8 |
| Histologic type | ||||||||||
| Endometrioid-adenocarcinoma | 29 | 1 (3.0) | 3 (15.2) | 4 (33.2) | 10 (79.4) | 11 (86.7) | 1 | 6 | 12 | 10 |
| Serous-adenocarcinoma | 31 | 1 (3.5) | 3 (17.5) | 7 (38.0) | 8 (79.2) | 12 (89.6) | 1 | 4 | 10 | 16 |
| Grade | ||||||||||
| G1 | 28 | 1 (3.2) | 3 (14.8) | 6 (36.0) | 8 (78.2) | 10 (88.5) | 1 | 6 | 12 | 9 |
| G2 | 18 | 1 (3.5) | 2 (16.6) | 5 (36.5) | 5 (78.6) | 5 (88.5) | 1 | 4 | 5 | 8 |
| G3 | 14 | 1 (3.6) | 1 (20.8) | 2 (37.6) | 4 (62.5) | 6 (91.8) | 1 | 1 | 3 | 9 |
| Myometrial invasion | ||||||||||
| <50% | 45 | 2 (2.8) | 4 (20.6) | 8 (40.1) | 15 (64.8) | 16 (90.7) | 2 | 12 | 8 | 23 |
| ≥50% | 15 | 0 | 1 (22.3) | 1 (35.7) | 1 (64.0) | 12 (91.4) | 0 | 0 | 5 | 10 |
| Lymph node metastasis | ||||||||||
| No | 47 | 2 (2.8) | 5 (19.9) | 9 (37.4) | 13 (63.2) | 18 (91.1) | 2 | 11 | 10 | 24 |
| Yes | 13 | 0 | 0 | 1 (39.7) | 2 (65.6) | 10 (91.2) | 0 | 0 | 3 | 10 |
BMI-1, B-lymphoma Mo-MLV insertion region 1; FIGO, International Federation of Gynecology and Obstetrics staging system.